DR. REDDY'S LABORATORIES, INC. AND CLINTEC-INTERNATIONAL GMBH ANNOUNCE CO-DEVELOPMENT OF ANTI-CANCER COMPOUND DRF 1042

Dr. Reddy's Laboratories and ClinTec International announced that they have entered into an agreement for the joint development of an anti-cancer compound, DRF 1042, belonging to the Topoisomerase inhibitors class of compounds for use as potential treatment of various types of cancer. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31375&full=1)